{"id":36705,"date":"2025-11-03T22:46:16","date_gmt":"2025-11-03T22:46:16","guid":{"rendered":"https:\/\/americanfinancecore.com\/index.php\/2025\/11\/03\/kimberly-clark-to-buy-kenvue-in-48-7-billion-deal\/"},"modified":"2025-11-03T22:46:16","modified_gmt":"2025-11-03T22:46:16","slug":"kimberly-clark-to-buy-kenvue-in-48-7-billion-deal","status":"publish","type":"post","link":"https:\/\/americanfinancecore.com\/index.php\/2025\/11\/03\/kimberly-clark-to-buy-kenvue-in-48-7-billion-deal\/","title":{"rendered":"Kimberly-Clark to buy Kenvue in $48.7 billion deal"},"content":{"rendered":"<p class=\"body-graf\">Kimberly-Clark said on Monday it will buy Tylenol maker Kenvue KVUE.N in a cash-and-stock deal valued at about $48.7 billion, to create one of the biggest consumer health goods companies in the United States.<\/p>\n<p class=\"body-graf\">Shares of Kenvue were up 18% in premarket trading, while Kimberly-Clark\u2018s shares were down 12.5%.<\/p>\n<div><\/div>\n<p class=\"body-graf\">Kenvue has been under a strategic review, leadership shake-up, and mounting litigation risks. It came under fresh scrutiny following President Donald Trump\u2019s comments linking its popular pain medicine Tylenol to autism.<\/p>\n<p class=\"body-graf\">The deal will bring together brands including Neutrogena, Huggies and Kleenex under a consumer health and personal care company with expected combined annual revenues of roughly $32 billion.<\/p>\n<p class=\"body-graf\">Sources in June told Reuters the strategic review of its operations could include a sale or breakup of the company that had been spun off from healthcare conglomerate Johnson &amp; Johnson JNJ.N in 2023.<\/p>\n<p class=\"endmark body-graf\">Kenvue\u2018s shareholders will receive $3.50 per share and 0.15 Kimberly-Clark shares for each Kenvue share held. That implies a per-share deal value of $21.01, or an equity value of $40.32 billion, according to Reuters calculations.<\/p>\n\n<div>This post appeared first on NBC NEWS<\/div>","protected":false},"excerpt":{"rendered":"<p>Kimberly-Clark said on Monday it will buy Tylenol maker Kenvue KVUE.N in a cash-and-stock deal valued at about $48.7 billion, to create one of the biggest consumer health goods companies in the United States. Shares of Kenvue were up 18% in premarket trading, while Kimberly-Clark\u2018s shares were down 12.5%. Kenvue has been under a strategic <\/p>\n","protected":false},"author":0,"featured_media":36706,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":{"0":"post-36705","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"_links":{"self":[{"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/posts\/36705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/comments?post=36705"}],"version-history":[{"count":0,"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/posts\/36705\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/media\/36706"}],"wp:attachment":[{"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/media?parent=36705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/categories?post=36705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/americanfinancecore.com\/index.php\/wp-json\/wp\/v2\/tags?post=36705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}